Analyst Price Target is $101.00
▲ +23.08% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for LivaNova in the last 3 months. The average price target is $101.00, with a high forecast of $117.00 and a low forecast of $84.00. The average price target represents a 23.08% upside from the last price of $82.06.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in LivaNova. This rating has held steady since April 2020, when it changed from a Hold consensus rating.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products. The Neuromodulation segment designs, develops, and markets Neuromodulation therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression (DTD), and obstructive sleep apnea. The company was founded in 1987 and is headquartered in London, the United Kingdom.